BHVN - Biohaven Pharmaceutical Holding Company Ltd.

NYSE - NYSE Delayed price. Currency in USD
65.83
+1.79 (+2.80%)
At close: 4:00PM EDT

65.83 0.00 (0.00%)
After hours: 4:15PM EDT

Stock chart is not supported by your current browser
Previous close64.04
Open64.55
Bid65.66 x 800
Ask67.99 x 1000
Day's range63.97 - 66.37
52-week range26.56 - 78.75
Volume702,527
Avg. volume771,634
Market cap3.853B
Beta (5Y monthly)1.42
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Bloomberg

    Khloe Kardashian Adds Biohaven Migraine Drug to Brand Touts

    (Bloomberg) -- Khloe Kardashian is adding another role to her already busy schedule, migraine ambassador.The social influencer, who has been criticized for past associations with weight loss teas and smoothies has joined forces with Biohaven Pharmaceutical Holding Co. to promote its migraine medicine, Nurtec ODT. Sales of the tablet in the first quarter were $1.2 million after the drug was approved in February.Nurtec ODT is seen generating about $50 million in revenue this year and topping $1 billion by 2024, according to the average of analysts’ estimates. Time will tell if its association with a Kardashian will spur the migraine medicine into what the industry calls blockbuster status sooner.More women suffer from migraines than men, and a smattering of new drugs has offered hope for the often disabling condition. Biohaven faces stiff competition from large-cap drugmakers like Amgen Inc. and the Danish drug company H. Lundbeck A/S. Shares in New Haven Connecticut-based Biohaven rose as much as 3.6% on Wednesday after the announcement.(Updates shares in fourth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • 3 Reasons Why Biohaven Pharmaceuticals' Stock Is Taking Off
    Motley Fool

    3 Reasons Why Biohaven Pharmaceuticals' Stock Is Taking Off

    A hot new migraine drug, positive financials, and several promising drug candidates in late-stage trials are luring investors to this stock.

  • Why Biohaven (BHVN) Might Surprise This Earnings Season
    Zacks

    Why Biohaven (BHVN) Might Surprise This Earnings Season

    Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Does Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Have A High Beta?
    Simply Wall St.

    Does Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Have A High Beta?

    Anyone researching Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) might want to consider the historical...

  • Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock
    Zacks

    Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock

    Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.

  • Options Traders Expect Huge Moves in Biohaven (BHVN) Stock
    Zacks

    Options Traders Expect Huge Moves in Biohaven (BHVN) Stock

    Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

  • Have Insiders Been Buying Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Shares?
    Simply Wall St.

    Have Insiders Been Buying Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...